Influenza vaccines market seen topping $13 billion by 2030
The global influenza vaccines market is projected to grow at a 7.6% CAGR through the forecast period and exceed $13 billion by 2030, according to The Business Research Company. North America is expected to lead the market, while inactivated vaccines remain the largest segment and CSL Limited held the top market share in 2025.
Why it matters: - Influenza vaccines are a core public health tool for preventing seasonal flu outbreaks. - The market’s growth points to continued spending on prevention, immunization infrastructure and next-generation vaccine formats. - The forecast suggests influenza vaccines will remain a specialized but important slice of both the antivirals market and the broader pharmaceuticals industry.
What happened: - The Business Research Company released its Global Influenza Vaccines Global Market Report 2026, covering market size, trends and forecasts for 2026-2035. - The report projects the influenza vaccines market will exceed $13 billion by 2030. - The market is forecast to grow at a 7.6% CAGR over the forecast period. - The report also says the market will grow at an 8% CAGR through 2030. - Request a free sample of the report.
The details: - The report says influenza vaccines will account for about 8% of the broader antivirals market by 2030, compared with a projected antivirals market size of about $162 billion. - Influenza vaccines are expected to represent nearly 1% of the global pharmaceuticals market, which is projected to reach $2,496 billion by 2030. - North America is projected to be the largest regional market in 2030 at $5.1 billion, up from $3.7 billion in 2025. - North America’s regional CAGR is projected at 7%. - The United States is expected to be the largest single-country market in 2030 at $4.7 billion, up from $3.4 billion in 2025. - The U.S. market is projected to grow at a 6% CAGR. - Inactivated vaccines are projected to be the largest segment, reaching 79% of the market, or about $10 billion, in 2030. - Quadrivalent and trivalent vaccines make up the valency split. - Injection and nasal spray are the main administration routes. - Pediatric and adult groups are the age-based segments. - Hospitals, pharmacies, government and institutional supply, and other channels make up the distribution mix. - The report says early immunization campaigns are one growth driver, with annual prevention efforts before flu season supporting uptake. - The report says rising healthcare spending is another driver, supporting immunization infrastructure, procurement and vaccine access. - The report says growing awareness of flu vaccination benefits is also lifting demand. - Inactivated and live attenuated vaccines are expected to add more than $4 billion in combined value by 2030. - Between 2025 and 2030, the inactivated vaccine segment is expected to grow by $3 billion and the live attenuated segment by $1 billion. - CSL Limited was the top seller in 2025 with 20% of the global market. - Sanofi S.A. held 19% in 2025. - GlaxoSmithKline plc held 4% in 2025. - Daiichi Sankyo Company Limited and AstraZeneca each held 3% in 2025. - Sinovac Biotech Co. Ltd., Viatris Inc., Abbott Laboratories and China National Pharmaceutical Group Corporation each held 2% in 2025. - SK Bioscience held 1% in 2025. - The top 10 players accounted for 58% of revenue in 2025. - The report identifies at-home vaccine administration as a notable trend, citing AstraZeneca’s August 2025 launch of FluMist Home, an FDA-approved program that delivers FLUMIST directly to patients. - FluMist Home includes needle-free administration, digital eligibility screening and temperature-controlled delivery. - Access the detailed report.
Between the lines: - The market is highly concentrated, which reflects the technical, regulatory and manufacturing barriers to launching and scaling influenza vaccines. - The top companies appear to be defending share through broader portfolios, manufacturing investment, cold-chain expansion and new delivery models. - At-home delivery and pharmacy-based access suggest the competitive focus is shifting beyond formulation alone to convenience and distribution. - The report’s emphasis on AI-enabled development and advanced vaccine platforms points to a market where speed, scalability and regulatory execution matter as much as demand.
What's next: - The report expects continued growth from strain-matched seasonal vaccines, broader access across age groups and expanded delivery options. - Further investment in manufacturing capacity, cold-chain logistics and digital vaccination tracking is likely to support market expansion. - Public and private immunization programs are expected to remain central to demand through 2030. - Follow the company’s announcement
The bottom line: - Influenza vaccines are headed for steady growth, but the market remains dominated by a small group of large players with the scale to meet regulatory, manufacturing and distribution demands.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Smart's Business Wire
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.